Skip to Content

Findings from the SPOTLIGHT Study Demonstrate the Power of the New Biomarker Claudin-18.2.

In this MEDtalk, Professor of Gastrointestinal Oncology Jaffer A. Ajani, MD Anderson Cancer Center, USA, presents the most recent efficacy and safety findings from the phase III SPOTLIGHT study. This study evaluates the use of zolbetuximab in conjunction with mFOLFOX6 as a first-line treatment option for patients diagnosed with claudin-18 isoform 2-positive (CLDN18.2+), HER2-negative, locally advanced (LA) unresectable, or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. When combined with the results from the GLOW study, it becomes evident that claudin-18.2 has emerged as a new biomarker, not only in gastric cancer but also in oncology, presenting a legitimate new target for cancer treatment that holds great promise for the benefit of patients.

Jaffer Ajani

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top